Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.
The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform.
But Noom is the latest in a string of digital health companies to offer compounded versions of the medications as a cheaper alternative for consumers while demand for weight loss and diabetes drugs spikes. Hims & Hers and Sesame have launched similar programs in recent months — and the market for low-cost options has grown more competitive.
“Our position is that more supply, especially at a reasonable price, is needed right now, not less,” Noom CEO Geoff Cook told CNBC in an interview.
Wegovy and Ozempic belong to a highly popular class of medications called GLP-1s, which mimic certain gut hormones to tamp down a patient’s appetite and regulate their blood sugar. The compounded versions are custom-made alternatives to the brand drugs, and they can be produced when brand-name treatments are in shortage.
Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Wegovy and Ozempic both cost roughly $1,000 per month before insurance. Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Spiking demand can also make it difficult for many patients to find the branded treatments.
Cook said consumers will pay $149 for their first month in Noom’s program and $279 for the following months as the dose of their medication increases.
The U.S. Food and Drug Administration does not review the safety and efficacy of compounded products, and the agency has urged consumers to take the approved, branded GLP-1 medications when they are available. However, the FDA does inspect some outsourcing facilities that compound drugs, according to its website.
Noom said it is working with an FDA-regulated 503B compounding pharmacy to provide its medication for its new program, which is called Noom GLP-1 RX.
“The drug manufacturer we’re working with generates 20 generic medications, epinephrine being one of them — a lifesaving medication that’s available in hospitals all across the United States,” Dr. Adonis Saremi, chief medical officer of Noom, told CNBC in an interview. “So we’re really confident and happy with our vetting process.”
The company said ithas also introduced a way for participants to taper off the compounded treatment if they would like to stop taking it. GLP-1s are intended for long-term use, which means some patients may end up taking them indefinitely.
Cook said Noom has seen both anecdotal and real-world evidence that patients are able to maintain weight loss after they stop taking the drugs. Six out of seven patients are off GLP-1s by the two-year mark anyway, he said.
“It’s prescribed by the doctor, the person takes their medicine, they lose weight, but then life happens,” Cook said. “They eventually stop taking the medication, or their insurance stops covering it, they’ll change a job [so] it’s no longer covered.”
Cook said not everyone will be able to taper off the medication, so some people will likely end up taking it indefinitely. The company will provide a free year of Noom or “substantial medication discounts” to anyone who regains the weight within 18 months after following its program for a year, it said in a release.
Consumers can get started with the Noom GLP-1 RX program by filling out an intake form on the website. Noom said one of its contracted, obesity-trained doctors will review the intake form and decide if the compounded medication is appropriate for that patient. If so, the drugs will arrive at their door within a week, Noom said.
Participants will learn how to inject their medication, and they can use a chat feature to talk one-on-one with a coach and their Noom clinician, the company said. They’ll also have access to a range of psychology-based programming and tools to help keep them from losing muscle mass, such as features for tracking protein intake and engaging in resistance training, Noom said.
And if users decide they are ready to move off the medication, they can chat with their clinician or tap “initiate taper” in their settings, Noom said.
“I think there’s a lot of folks who don’t want to be on a medication for the rest of their lives, and in any event, people aren’t doing that in the real world,” Cook said. “Our goal is just not to sell more medications. It’s to drive sustained weight loss outcomes.”
A woman holds a cell phone featuring the DeepSeek logo, with the Nvidia logo displayed in the background.
Nurphoto | Nurphoto | Getty Images
As China and the U.S. compete in artificial intelligence, Southeast Asia should draw from the best of both countries while building its own technologies, panelists said at CNBC’s East Tech West 2025 conference on June 27 in Bangkok, Thailand.
Julian Gorman, head of Asia-Pacific at mobile network trade organization GSMA, said it would be a negative development if Southeast Asia was forced to choose between either superpower.
“Southeast Asia is very dependent on both economies, both China and America. I think it’s pretty hard to consider that they would go one way or the other,” Gorman said.
“It’s very important that we continue to focus on not fragmenting the technology, standardizing it, and working so that technology transcends geopolitics and ultimately is used for good,” he added.
The spread of U.S. and Chinese AI companies into new global markets has been a big trend this year as both Beijing and Washington seek more global influence in advanced technologies.
U.S. and China offerings
According to George Chen, managing director and co-chair of digital practice for The Asia Group, Southeast Asia had initially been leaning towards AI models from the U.S., such as those from Google and Microsoft.
However, the emergence of China’s DeepSeek has propelled the popularity of the company’s models in Southeast Asia due to its low cost and open-source licensing, which can be used to build on and adapt models to regional priorities.
Open-source generally refers to software in which the source code is made freely available, allowing anyone to view, modify and redistribute it. Large language model players in China have been leaning into this business model since DeepSeek’s debut.
Previous panels at East Tech West have flagged open-source models as an important tool for regions outside of China and the U.S. to build their own sovereign AI capabilities.
Meanwhile, on the hardware side, the U.S. remains a leader in AI processors through chip giant Nvidia. While the U.S. has restricted China’s access to these chips, they remain on the market for Southeast Asia – which Chen suggested the region continue to take advantage of.
However, Chen noted that there is a possibility that the AI landscape could change dramatically in a decade, with China being able to provide more affordable alternatives to Nvidia.
“Don’t take a side easily and too quickly. Think about how to maximize your economic potential,” he suggested.
GSMA’s Gorman pointed out that facing this “balancing act” between the superpowers is not new for Southeast Asia. For example, the region’s mobility industry heavily relies on Chinese tech manufacturing and hardware, as well as the U.S. in other areas such as telecommunications.
Southeast Asia’s edge
Though the U.S. and China are clearly ahead in building advanced AI models, Southeast Asia has its own edge in the global AI space, panelists said.
“If you think about AI as a technology, eventually you need to apply it to a real product or service. That’s how people can use it,” said The Asia Group’s Chen.
The region has a strong app environment which offers “great potential,” he added. “The demographic is young, which means the potential for talent is always there, and R&D cost is relatively cheaper than other places.”
Still, Southeast Asia should aim to bring in companies with advanced capabilities that domestic industries can learn from and benefit from – a strategy that China employed to catch up to the West in advanced technologies, said Chen.
Leader in AI regulation?
According to GSMA’s Gorman, Southeast Asia can serve as a neutral ground between China and the U.S., where the two sides can come together and engage in high-level dialogues on how to apply AI responsibly.
Southeast Asia can also play a proactive role in AI regulation itself, he said, citing recent examples of regulatory leadership from the region, such as Singapore’s Shared Responsibility Framework for tackling international scams and fraud.
So far, there have been few global regulations on AI. While the EU has adopted a policy, the U.S. and ASEAN countries have yet to follow suit.
Chen added that the region will need to band together and adopt common frameworks to gain a more prominent seat at the table of global AI development and regulation.
Almost 600 people have signed an open letter to leaders at venture firm Sequoia Capital after one of its partners, Shaun Maguire, posted what the group described as a “deliberate, inflammatory attack” against the Muslim Democratic mayoral candidate in New York City.
Maguire, a vocal supporter of President Donald Trump, posted on X over the weekend that Zohran Mamdani, who won the Democratic primary last month, “comes from a culture that lies about everything” and is out to advance “his Islamist agenda.”
The post had 5.3 million views as of Monday afternoon. Maguire, whose investments include Elon Musk’s SpaceX and X as well as artificial intelligence startup Safe Superintelligence, also published a video on X explaining the remark.
Those signing the letter are asking Sequoia to condemn Maguire’s comments and apologize to Mamdani and Muslim founders. They also want the firm to authorize an independent investigation of Maguire’s behavior in the past two years and post “a zero-tolerance policy on hate speech and religious bigotry.”
They are asking the firm for a public response by July 14, or “we will proceed with broader public disclosure, media outreach and mobilizing our networks to ensure accountability,” the letter says.
Sequoia declined to comment. Maguire didn’t respond to a request for comment, but wrote in a post about the letter on Wednesday that, “You can try everything you want to silence me, but it will just embolden me.”
Among the signees are Mudassir Sheikha, CEO of ride-hailing service Careem, and Amr Awadallah, CEO of AI startup Vectara. Also on the list is Abubakar Abid, who works in machine learning Hugging Face, which is backed by Sequoia, and Ahmed Sabbah, CEO of Telda, a financial technology startup that Sequoia first invested in four years ago.
At least three founders of startups that have gone through startup accelerator program Y Combinator added their names to the letter.
Sequoia as a firm is no stranger to politics. Doug Leone, who led the firm until 2022 and remains a partner, is a longtime Republican donor, who supported Trump in the 2024 election. Following Trump’s victory in November, Leone posted on X, “To all Trump voters: you no longer have to hide in the shadows…..you’re the majority!!”
By contrast, Leone’s predecessor, Mike Moritz, is a Democratic megadonor, who criticized Trump and, in August, slammed his colleagues in the tech industry for lining up behind the Republican nominee. In a Financial Times opinion piece, Moritz wrote Trump’s tech supporters were “making a big mistake.”
“I doubt whether any of them would want him as part of an investment syndicate that they organised,” wrote Moritz, who stepped down from Sequoia in 2023, over a decade after giving up a management role at the firm. “Why then do they dismiss his recent criminal conviction as nothing more than a politically inspired witch-hunt over a simple book-keeping error?”
Neither Leone nor Moritz returned messages seeking comment.
Roelof Botha, Sequoia’s current lead partner, has taken a more neutral stance. Botha said at an event last July that Sequoia as a partnership doesn’t “take a political point of view,” adding that he’s “not a registered member of either party.” Boelof said he’s “proud of the fact that we’ve enabled many of our partners to express their respected individual views along the way, and given them that freedom.”
Maguire has long been open with his political views. He said on X last year that he had “just donated $300k to President Trump.”
Mamdani, a self-described democratic socialist, has gained the ire of many people in tech and in the business community more broadly since defeating former New York Gov. Andrew Cuomo in the June primary.
Samsung signage during the Nvidia GPU Technology Conference (GTC) in San Jose, California, US, on Thursday, March 20, 2025.
David Paul Morris | Bloomberg | Getty Images
South Korea’s Samsung Electronics on Tuesday forecast a 56% fall in profits for the second as the company struggles to capture demand from artificial intelligence chip leader Nvidia.
The memory chip and smartphone maker said in its guidance that operating profit for the quarter ending June was projected to be around 4.6 trillion won, down from 10.44 trillion Korean won year over year.
The figure is a deeper plunge compared to smart estimates from LSEG, which are weighted toward forecasts from analysts who are more consistently accurate.
According to the smart estimates, Samsung was expected to post an operating profit of 6.26 trillion won ($4.57 billion)for the quarter. Meanwhile, Samsung projected its revenue to hit 74 trillion won, falling short of LSEG smart estimates of 75.55 trillion won.
Samsung is a leading player in the global smartphone market and is also one of the world’s largest makers of memory chips, which are utilized in devices such as laptops and servers.
However, the company has been falling behind competitors like SK Hynix and Micron in high-bandwidth memory chips — an advanced type of memory that is being deployed in AI chips.
“The disappointing earnings are due to ongoing operating losses in the foundry business, while the upside in high-margin HBM business remains muted this quarter,” MS Hwang, Research Director at Counterpoint Research, said about the earnings guidance.
SK Hynix, the leader in HBM, has secured a position as Nvidia’s key supplier. While Samsung has reportedly been working to get the latest version of its HBM chips certified by Nvidia, a report from a local outlet suggests these plans have been pushed back to at least September.
The company did not respond to a request for comment on the status of its deals with Nvidia.
Ray Wang, Research Director of Semiconductors, Supply Chain and Emerging Technology at Futurum Group told CNBC that it is clear that Samsung has yet to pass Nvidia’s qualification for its most advanced HBM.
“Given that Nvidia accounts for roughly 70% of global HBM demand, the delay meaningfully caps near-term upside,” Wang said. He noted that while Samsung has secured some HBM supply for AI processors from AMD, this win is unlikely to contribute to second-quarter results due to the timing of production ramps.
Reuters reported in September that Samsung had instructed its subsidiaries worldwide to cut 30% of staff in some divisions, citing sources familiar with the matter.
